Hi Gregory,

As an experienced biotech investor, I wanted to make sure I introduced you to Regenxbio [NASDAQ: RGNX], a regenerative medicine company with three assets in pivotal trials that are set to reach critical milestones this year. Regenxbio is currently targeting Hunter Syndrome, Duchenne Muscular Dystrophy, and Chronic Retinal Disease with treatments that have the potential to become standard of care in markets worth a total of $26B.

In addition to its three late-stage clinical assets, Regenxbio is differentiated from other gene therapy companies in several ways:

• They are one of a few gene therapy companies worldwide with a cGMP facility capable of production at commercial scale.
• They already have partnerships in place with global pharmaceutical companies including Abbvie, Nippon Shinyaku, and Novartis.
• Their NAV Platform technology is capable of developing broad applications across multiple disease states, creating a robust pipeline of future opportunities.
• Their Hunter Syndrome program has received a Priority Review Voucher worth $150M.

Regenxbio has a strong balance sheet to fund operations into the second half of 2026 and multiple revenue streams currently in place including milestone payments and licensing deals.

If you’d like to learn more about Regenxbio’s unique approach to gene therapy and the opportunity this is creating for investors, please reply to this email. I will be happy to connect you with the leaders of the company.

Warm Regards,

Pam

Pam Jennemyr

Client Success Manager

LinkedIn

FORCE Family Office

1460 Broadway
New York, NY  10036